PubRank

Enzo Maria Ruggeri

Author PubWeight™ 19.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007 1.58
2 Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? J Clin Oncol 2006 1.45
3 Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. Eur Urol 2006 1.38
4 Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011 1.24
5 Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010 1.20
6 Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009 1.13
7 Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004 1.04
8 Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005 0.94
9 Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 2010 0.94
10 Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol 2011 0.86
11 Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007 0.86
12 Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 2013 0.85
13 Rhabdomyolysis from erlotinib: a case report. Tumori 2011 0.85
14 Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006 0.84
15 First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013 0.80
16 Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. Int J Clin Oncol 2012 0.79
17 Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study. Cancer Chemother Pharmacol 2005 0.78
18 New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 2005 0.77
19 HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? J Clin Oncol 2004 0.75
20 Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005 0.75
21 Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 2015 0.75
22 Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert Opin Investig Drugs 2007 0.75
23 Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? J Steroid Biochem Mol Biol 2003 0.75